{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:47:14Z","timestamp":1789602434898,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,4,11]],"date-time":"2003-04-11T00:00:00Z","timestamp":1050019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2003,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several side effects of interferon\u2010\u03b1\u20102b (IFN\u2010\u03b1) therapy have been described. Pulmonary side effects have seldom been reported. The four patients we describe all developed respiratory disorders while being treated with IFN\u2010\u03b1 for hematological malignancies. We point out the similarities and differences noticed concerning the clinical course, pathological findings, and prognosis in the four different cases. Also, in addition to our review of the literature, we discuss the possible mechanisms involved in development of lung symptoms. In three patients the pulmonary disorder seems to have been caused by a cell\u2010mediated immunological side effect in the form of interstitial pneumonitis. In one patient the symptoms were most likely caused by an autoimmunologic reaction, primarily engaging the vascular system, initially in the lungs. The single pathological finding existing in all four cases was the marked decrease in carbon monoxide diffusion capacity when performing spirometry. This was not necessarily associated with the existence of radiological findings. The decrease in diffusion capacity and the clinical symptoms were completely reversible in three of the patients, either spontaneously after the withdrawal of IFN\u2010\u03b1 or after treatment with corticosteroids. Our conclusion is that IFN\u2010\u03b1, on rare occasions, can cause serious pulmonary side effects when used to treat both lympho\u2010 and myeloproliferative hematological malignancies. When pulmonary symptoms are evaluated during IFN\u2010\u03b1 therapy, spirometry, including estimation of carbon monoxide diffusion capacity, high\u2010resolution computerized tomography, and ultracardiography should be used. Am. J. Hematol. 73:54\u201358, 2003. \u00a9 2003 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.10319","type":"journal-article","created":{"date-parts":[[2003,4,14]],"date-time":"2003-04-14T10:02:38Z","timestamp":1050314558000},"page":"54-58","source":"Crossref","is-referenced-by-count":35,"title":["Pulmonary side effects of interferon\u2010\u03b1 therapy in patients with hematological malignancies"],"prefix":"10.1002","volume":"73","author":[{"given":"Patrik","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"R\u00f6djer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,4,11]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1200\/JCO.1995.13.9.2401","article-title":"Immune\u2010mediated and unusual complications during interferon alpha therapy in CML","volume":"9","author":"Sacchi S","year":"1995","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0300-483X(95)03124-X"},{"issue":"3","key":"e_1_2_1_4_2","first-page":"63","article-title":"Intensive treatment in order to minimize the Ph\u2010positive clone in CML","volume":"17","author":"Simonsson B","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.306.6882.896-c"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02361253"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.3.939"},{"key":"e_1_2_1_8_2","first-page":"1905","article-title":"Interstitial pneumonia induced by interferon therapy in type C hepatitis","volume":"7","author":"Karino Y","year":"1994","journal-title":"Nippon Rinsho"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.96.09122691"},{"key":"e_1_2_1_10_2","first-page":"389","article-title":"A possible mechanism of interstitial pneumonia during interferon therapy with sho\u2010saiko\u2010to","volume":"4","author":"Murakami K","year":"1995","journal-title":"Nippon Kyobu Shikkan Gakkai Zasshi"},{"key":"e_1_2_1_11_2","first-page":"1361","article-title":"Five cases of drug\u2010induced pneumonitis due to Sho\u2010saiko\u2010to or interferon\u2010alpha or both","volume":"12","author":"Nakagawa A","year":"1995","journal-title":"Nippon Kyobu Shikkan Gakkai Zasshi"},{"key":"e_1_2_1_12_2","first-page":"1308","article-title":"A case of interferon\u2010alpha\u2010induced pneumonitis","volume":"31","author":"Watanabe N","year":"1993","journal-title":"Nippon Kyobu Shikkan Gakkai Zasshi"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830470330"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.33.710"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.32.716"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000203687"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/15563659709001177"},{"key":"e_1_2_1_18_2","first-page":"1910","article-title":"Interstitial pneumonia following treatment with alpha\u2010interferon","volume":"24","author":"Lustman F","year":"1995","journal-title":"Presse Med"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90350-3"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2583::AID-CNCR14>3.0.CO;2-#"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.10319","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.10319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T12:48:33Z","timestamp":1700225313000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.10319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,11]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["10.1002\/ajh.10319"],"URL":"https:\/\/doi.org\/10.1002\/ajh.10319","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4,11]]}}}